Dr. Riffat Munir

Riffat Munir is a clinical microbiology researcher based in South Africa, recognized for expertise in diagnostic assay evaluation and implementation in high-burden settings. Recent work centers on tuberculosis and HIV-associated TB, including studies on Xpert MTB/XDR and expanded molecular screening strategies in hospitalized patients. Contributions to multicenter trials and laboratory-based accuracy studies highlight a strong focus on translating innovative diagnostics into routine care.

During the COVID-19 pandemic, Munir played a key role in independent evaluations of SARS-CoV-2 molecular assays and in developing practical guidance for rapid analytical performance assessments. This work supported regulatory decision-making and strengthened national testing capacity through rigorous validation of open-platform and multiplex PCR technologies.

Earlier publications reflect a background in microbial biotechnology and polyhydroxyalkanoate research, exploring gene expression, metabolic regulation, and biopolymer synthesis in Pseudomonas species. Collectively, the body of work demonstrates interdisciplinary strength spanning molecular microbiology, diagnostic innovation, and health systems impact in infectious diseases.